Impact of cetuximab conventional dosing on cetuximab-induced magnesium concentration under haemodialysis in head and neck cancer

NDT Plus

Volumn 1, Issue 3, 2008, Pages 196-197

  Thariat, Juliette ^a   Launay Vacher, Vincent ^b   Italiano, Antoine ^c   Santini, José ^c   Peyrade, Frederic ^c  

^a Centre Lacassagne   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c PASTEUR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; FIBRINOGEN; HEMOGLOBIN; MAGNESIUM;

ADULT; CASE REPORT; DIALYSATE; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; FIBRINOGEN BLOOD LEVEL; HEAD AND NECK CANCER; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOMAGNESEMIA; KIDNEY FAILURE; KIDNEY TUBULE ABSORPTION; LETTER; LOADING DRUG DOSE; LONG TERM EXPOSURE; MAGNESIUM BLOOD LEVEL; MALE; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 44449105021     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfn039     Document Type: Letter

References (4)

1. Tejpar S, Piessevaux H, Claes K et al. Magnesium wasting associated with epidermal growth-factor receptor-targeting antibodies in colorectal cancer: A prospective study. Lancet Oncol 2007; 8: 387-394.
2. Bonner JA, Harari PM, Giralt J et al. Radiotheraphy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578
3. Schlingman KP, Weber S, Peters M et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat Genet 2002; 31: 166-170
4. Groenestege WM, Thebault S, Van Der Wijst J et al. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest 2007; 117: 2260-2267